These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2839891)

  • 1. [The heparins: structure and pharmacology].
    Choay J
    Rev Prat; 1988 May; 38(15):917-24. PubMed ID: 2839891
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemistry of heparin and low molecular weight heparin.
    Nielsen JI; Ostergaard P
    Acta Chir Scand Suppl; 1988; 543():52-6. PubMed ID: 2847458
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of calcium ions on the interactions between antithrombin and factor Xa mediated by variously sulfated, semisynthetic low-molecular-weight heparins.
    Sissi C; Lucatello L; Naggi A; Torri G; Palumbo M
    Semin Thromb Hemost; 2002 Aug; 28(4):355-60. PubMed ID: 12244482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New data on heparin (a review)].
    Bychkov SM
    Vopr Med Khim; 1981; 27(6):726-36. PubMed ID: 7039095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of the low-molecular-weight heparins.
    Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1996; 22 Suppl 2():13-8. PubMed ID: 8946614
    [No Abstract]   [Full Text] [Related]  

  • 6. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an amidolytic test for comparative calibration of HMW- and LMW-heparins.
    Münstedt K; Bleyl H; Róka L
    Thromb Res; 1991 Oct; 64(1):23-31. PubMed ID: 1663665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization.
    Fareed J; Walenga JM; Hoppensteadt D; Racanelli A; Coyne E
    Semin Thromb Hemost; 1989 Oct; 15(4):440-63. PubMed ID: 2554505
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antithrombin III].
    Boyer-Neumann C; Wolf M; Larrieu MJ
    Ann Biol Clin (Paris); 1987; 45(2):175-80. PubMed ID: 3619143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of inhibitors and the mechanisms of action of antithrombin III.
    Rosenberg RD; Oosta GM
    Prog Clin Biol Res; 1981; 72():179-203. PubMed ID: 7335648
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of an automated analyzer in the evaluation of antithrombin III and heparin.
    Scully MF
    Semin Thromb Hemost; 1983 Oct; 9(4):309-20. PubMed ID: 6658462
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure of heparins and their fragments.
    Casu B
    Nouv Rev Fr Hematol (1978); 1984; 26(4):211-9. PubMed ID: 6473092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemistry of heparin (author's transl)].
    Yosizawa Z; Ototani N; Kosakai M
    Rinsho Ketsueki; 1981 Jul; 22(7):994-1000. PubMed ID: 7035720
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of heparin and low molecular weight heparins on platelets.
    Vermylen JG
    Semin Thromb Hemost; 1993; 19 Suppl 1():20-1. PubMed ID: 8395723
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anticoagulant and antithrombotic effects of low molecular weight heparin].
    Bashkov GV; Kalishevskaia TM; Bako N
    Biull Eksp Biol Med; 1988 Oct; 106(10):399-402. PubMed ID: 2847825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heparin in therapeutics (author's transl)].
    Capel P
    Rev Med Brux; 1981 Mar; 2(3):181-9. PubMed ID: 7015442
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.